ARK Investment Management LLC Has $189.29 Million Stake in Twist Bioscience Corporation $TWST

ARK Investment Management LLC raised its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,726,808 shares of the company’s stock after acquiring an additional 326,367 shares during the period. Twist Bioscience makes up about 1.1% of ARK Investment Management LLC’s portfolio, making the stock its 25th biggest holding. ARK Investment Management LLC owned approximately 11.14% of Twist Bioscience worth $189,292,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of TWST. Dimensional Fund Advisors LP raised its stake in Twist Bioscience by 8.6% in the third quarter. Dimensional Fund Advisors LP now owns 790,893 shares of the company’s stock valued at $22,252,000 after purchasing an additional 62,300 shares in the last quarter. William Blair Investment Management LLC increased its holdings in Twist Bioscience by 6.0% in the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock valued at $116,564,000 after buying an additional 235,679 shares during the period. Rafferty Asset Management LLC raised its position in shares of Twist Bioscience by 51.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company’s stock valued at $3,216,000 after buying an additional 38,608 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Twist Bioscience by 26.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after acquiring an additional 1,349,867 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth approximately $440,000.

Twist Bioscience Trading Up 3.0%

Shares of TWST stock opened at $48.06 on Thursday. The business’s fifty day moving average is $43.03 and its 200 day moving average is $34.31. The company has a market capitalization of $2.95 billion, a PE ratio of -37.55 and a beta of 2.23. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $57.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TWST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Barclays upped their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Evercore raised their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Finally, Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 7,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $45.65, for a total value of $319,550.00. Following the sale, the chief accounting officer directly owned 58,738 shares of the company’s stock, valued at approximately $2,681,389.70. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jan Johannessen sold 2,200 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $47.91, for a total value of $105,402.00. Following the completion of the sale, the director directly owned 17,754 shares in the company, valued at approximately $850,594.14. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 36,609 shares of company stock valued at $1,665,151. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.